By Sarah Yang, Media Relations
Academic research sponsored by industry has a strong track record of leading to innovative patents and licenses, challenging assumptions that corporate support skews science toward inventions that are less accessible and less useful to others than those funded by the government or non-profit organizations, according to a new analysis.
The findings, published today (Wednesday, March 19) in a commentary in the journal Nature, are based upon a study of two decades of records from the University of California system.
The authors, led by Brian Wright, UC Berkeley professor of agricultural and resource economics, analyzed 12,516 inventions and related licenses at nine UC campuses and three associated national laboratories. The inventions were disclosed between 1990 and 2005, and licensing activity was analyzed through 2010. Of the inventions, nearly 1,500 were supported at least partly by private industry. (UC Merced, the 10th UC campus, was not included because it opened in 2005.)
University research funded by industry yields inventions that were more likely to result in patents and licenses than federally funded research alone, an analysis finds. (iStockphoto)
The analysis found that industry-funded inventions yielded patents and licenses more frequently than federally sponsored ones, with results consistent across technical fields. The researchers also found that industry-sponsored inventions were more highly cited in subsequent patent applications — known as “forward citations” — the most widely used marker of a patent’s quality and importance. Each corporate-sponsored invention generated an average of 12.8 forward citations compared with 5.6 for federally sponsored inventions.
“This runs counter to the expectation that corporate-sponsored inventions have narrow applications, and so create … few benefits for others,” the authors wrote.
Locking up inventions for profit?
Because corporations usually get first crack at negotiating licenses to the inventions they sponsor, there is an assumption that corporations would tie up innovative discoveries in a way that restricts access to a broader audience.
To illustrate those concerns, the authors referenced reactions to a 1998 deal with Swiss pharmaceutical company Novartis to support biotechnology research at UC Berkeley, and to a research consortium, the Energy Biosciences Institute (EBI), funded by energy giant BP and led by UC Berkeley.
In both cases, critics expressed fears that corporate interests would stifle UC Berkeley’s public mission by locking up discoveries for industry profits. (The Novartis project yielded no patents, and EBI began too late to be included in the study.)
However, the intellectual property data analyzed by the authors indicate that industry has not been more likely than federally sponsored research to tie up research discoveries in exclusive licenses. Overall, corporate-funded inventions were licensed exclusively 74 percent of the time, while federally funded inventions were licensed exclusively 76 percent of the time. Notably, among the corporate-funded inventions with exclusive licenses, half seemed to go to third parties and not the sponsor.
Industry-funded research need not be locked up by corporate sponsors.
– Stephen Merrill, The National Academies
“We didn’t expect these results,” said Wright. “We thought companies would be interested in applied research that was closer to being products, and thus more likely to be licensed exclusively and less cited than federally funded counterparts, but that did not turn out to be the case.”
The authors acknowledged that they might not have identified all third-party licensees that were actually affiliated with the original corporate sponsor, but Wright said this does not affect the finding that licenses to corporate-funded inventions are not more likely to be exclusive.
“Industry-funded research need not be locked up by corporate sponsors if both the sponsored research office and the tech-transfer office take care in protecting and marketing the results,” said co-author Stephen Merrill, executive director of Science, Technology and Economic Policy at The National Academies.